How to Invest in Novo Nordisk A/S (NVO)

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Novo Nordisk A/S's investor relations page or your broker.

• Revenue (TTM): ~$40 billion (approximate, verify; reported in Danish kroner)
• Operating margin: ~45% (approximate, verify)
• Net margin: ~35% (approximate, verify)
• GLP-1 share of revenue: Majority of sales from semaglutide products (approximate)
• P/E (TTM): ~25x (approximate, verify; varies with the ADR price)
• Dividend: Pays a dividend; yield is modest (approximate, verify)
• Listing: NYSE ADR representing Danish B shares

Novo Nordisk has historically commanded a premium pharma multiple on the strength of GLP-1 growth and very high margins. The multiple is sensitive to GLP-1 market-share dynamics versus Eli Lilly, supply progress, and US pricing news; disappointing trial data or share loss can compress it quickly. All figures are approximate, are reported in Danish kroner and translated to dollars, and should be verified against the latest filings.

These are the investment theses NVO naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that show up alongside NVO in the same themes. Worth a look if you're thinking about diversification within a single thesis rather than concentration on one ticker.

There are three common ways to get NVO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NVO sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where NVO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Novo Nordisk (NVO) is a large-cap European pharma whose value hinges on the GLP-1 obesity and diabetes franchise. In a portfolio it behaves as a healthcare growth holding levered to one therapeutic class, with high margins and strong cash generation balanced against competition from Eli Lilly, manufacturing capacity limits, and pricing and reimbursement pressure. It is a currency-exposed ADR, not a domestic blue chip.